Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients

• Published in: Cancer chemotherapy and pharmacology Vol. 88; no. 3; pp. 533 - 542
• Main Authors: Helsby, Nuala, Yong, Minghan, Burns, Kathryn, Findlay, Michael, Porter, David
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.09.2021; Springer Nature B.V
• Subjects: Adult; Aged; Antineoplastic Agents, Alkylating - administration & dosage; Antineoplastic Agents, Alkylating - pharmacokinetics; Antineoplastic Agents, Alkylating - pharmacology; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Cancer Research; Cyclophosphamide; Cyclophosphamide - administration & dosage; Cyclophosphamide - analogs & derivatives; Cyclophosphamide - metabolism; Cyclophosphamide - pharmacokinetics; Cyclophosphamide - pharmacology; Cytochrome P-450 CYP2B6 - genetics; Cytochrome P-450 CYP2C19 - genetics; Cytochrome P450; Dosage; Dose-Response Relationship, Drug; Female; Genetic diversity; Genotype; Genotype & phenotype; Genotypes; Humans; Medicine; Medicine & Public Health; Middle Aged; Oncology; Original Article; Patients; Pharmacogenetics; Pharmacokinetics; Pharmacology/Toxicology; Phenotypes; Polymorphism, Single Nucleotide; Single-nucleotide polymorphism; Young Adult; Pharmacogenetics; Cyclophosphamide; CYP2B6; CYP2C19

Purpose Genetic variation in the activation of the prodrug cyclophosphamide (CP) by cytochrome P450 (CYP) enzymes has been shown to influence outcomes. However, CYP are also subject to phenoconversion due to either the effects of comedications or cancer associated down-regulation of expression. The...